



## ASX ANNOUNCEMENT

### CELLMID COMPLETES \$2M PLACEMENT

**SYDNEY, Wednesday, 13 March 2013: Cellmid Limited (ASX: CDY)** is pleased to advise that it has successfully completed the placement of 50M ordinary Shares at an issue price of 4 cents per share (\$0.04), and 30M options raising a total of \$2,030,000 before costs. The Placement was made pursuant to section 708 of the Corporations Act and was oversubscribed.

The issue price for the Shares is at the five day average volume weighted trading price (VWAP) of the Company's Shares immediately prior to the Placement and a premium to the 21 day traded VWAP. The Placement is not subject to Shareholders' approval.

The Options are unlisted and will be issued on the following terms:

- Option Issue Price: \$0.001
- Exercise Price: \$0.05
- Option Expiry Date: 19<sup>th</sup> March 2014

Cellmid will use the money raised to strengthen marketing of its Évolis hair growth products in Australia and overseas. In addition, funds will also be deployed to continue the Company's diagnostic and therapeutic antibody product development programs.

Cellmid's CEO Maria Halasz said "The Company has gone through solid growth in the 2013 financial year and met all of its product and licensing milestones which has been reflected in the strong interest in this capital raising round. Midkine, as a novel therapeutic and diagnostic target, represents multiple product development and licensing opportunities for Cellmid and we continue to unlock value for shareholders in 2013 and beyond."

The Company advises that a new research note prepared by RM Capital entitled "Strong investment thesis going forward: Multiple catalysts and upside opportunities – A rare find" is available on the Company's website.

End

Contact:

Andrew Bald, Company Secretary

T +612 9299 0311

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

**Advangen International Pty Ltd**

Advangen International Pty Ltd is a controlled entity of Cellmid Limited. Advangen develops and sells scientifically validated products to prevent and treat various forms of hair loss. The Company's products have well understood mechanism of action and have been extensively tested for safety and efficacy with published validation data. Advangen has two market ready product ranges, one for pharmacies (évolis®) and one for professional hair salons (Jo-Ju® and Lexilis®). In addition, the Company is developing midkine in a high performance formulation for the treatment of age related hair loss.